111 related articles for article (PubMed ID: 10406646)
21. Solid-phase synthesis of a nonpeptide RGD mimetic library: new selective alphavbeta3 integrin antagonists.
Sulyok GA; Gibson C; Goodman SL; Hölzemann G; Wiesner M; Kessler H
J Med Chem; 2001 Jun; 44(12):1938-50. PubMed ID: 11384239
[TBL] [Abstract][Full Text] [Related]
22. Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and functional activity.
Ashton WT; Sisco RM; Kieczykowski GR; Yang YT; Yudkovitz JB; Cui J; Mount GR; Ren RN; Wu TJ; Shen X; Lyons KA; Mao AH; Carlin JR; Karanam BV; Vincent SH; Cheng K; Goulet MT
Bioorg Med Chem Lett; 2001 Oct; 11(19):2597-602. PubMed ID: 11551758
[TBL] [Abstract][Full Text] [Related]
23. Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors.
Dai Y; Hartandi K; Soni NB; Pease LJ; Reuter DR; Olson AM; Osterling DJ; Doktor SZ; Albert DH; Bouska JJ; Glaser KB; Marcotte PA; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2008 Jan; 18(1):386-90. PubMed ID: 18023347
[TBL] [Abstract][Full Text] [Related]
24. Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity.
Spanka C; Glatthar R; Desrayaud S; Fendt M; Orain D; Troxler T; Vranesic I
Bioorg Med Chem Lett; 2010 Jan; 20(1):184-8. PubMed ID: 19931453
[TBL] [Abstract][Full Text] [Related]
25. Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists.
Xin Z; Serby MD; Zhao H; Kosogof C; Szczepankiewicz BG; Liu M; Liu B; Hutchins CW; Sarris KA; Hoff ED; Falls HD; Lin CW; Ogiela CA; Collins CA; Brune ME; Bush EN; Droz BA; Fey TA; Knourek-Segel VE; Shapiro R; Jacobson PB; Beno DW; Turner TM; Sham HL; Liu G
J Med Chem; 2006 Jul; 49(15):4459-69. PubMed ID: 16854051
[TBL] [Abstract][Full Text] [Related]
26. 2-aryloxy-4-alkylaminopyridines: discovery of novel corticotropin-releasing factor 1 antagonists.
Chen YL; Obach RS; Braselton J; Corman ML; Forman J; Freeman J; Gallaschun RJ; Mansbach R; Schmidt AW; Sprouse JS; Tingley Iii FD; Winston E; Schulz DW
J Med Chem; 2008 Mar; 51(5):1385-92. PubMed ID: 18288792
[TBL] [Abstract][Full Text] [Related]
27. 3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.
Younis Y; Douelle F; Feng TS; González Cabrera D; Le Manach C; Nchinda AT; Duffy S; White KL; Shackleford DM; Morizzi J; Mannila J; Katneni K; Bhamidipati R; Zabiulla KM; Joseph JT; Bashyam S; Waterson D; Witty MJ; Hardick D; Wittlin S; Avery V; Charman SA; Chibale K
J Med Chem; 2012 Apr; 55(7):3479-87. PubMed ID: 22390538
[TBL] [Abstract][Full Text] [Related]
28. Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain.
Hoyt SB; London C; Ok H; Gonzalez E; Duffy JL; Abbadie C; Dean B; Felix JP; Garcia ML; Jochnowitz N; Karanam BV; Li X; Lyons KA; McGowan E; Macintyre DE; Martin WJ; Priest BT; Smith MM; Tschirret-Guth R; Warren VA; Williams BS; Kaczorowski GJ; Parsons WH
Bioorg Med Chem Lett; 2007 Nov; 17(22):6172-7. PubMed ID: 17889534
[TBL] [Abstract][Full Text] [Related]
29. Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors.
Liang J; van Abbema A; Balazs M; Barrett K; Berezhkovsky L; Blair W; Chang C; Delarosa D; DeVoss J; Driscoll J; Eigenbrot C; Ghilardi N; Gibbons P; Halladay J; Johnson A; Kohli PB; Lai Y; Liu Y; Lyssikatos J; Mantik P; Menghrajani K; Murray J; Peng I; Sambrone A; Shia S; Shin Y; Smith J; Sohn S; Tsui V; Ultsch M; Wu LC; Xiao Y; Yang W; Young J; Zhang B; Zhu BY; Magnuson S
J Med Chem; 2013 Jun; 56(11):4521-36. PubMed ID: 23668484
[TBL] [Abstract][Full Text] [Related]
30. Rapid inhibition of thyroxine-induced bone resorption in the rat by an orally active vitronectin receptor antagonist.
Hoffman SJ; Vasko-Moser J; Miller WH; Lark MW; Gowen M; Stroup G
J Pharmacol Exp Ther; 2002 Jul; 302(1):205-11. PubMed ID: 12065718
[TBL] [Abstract][Full Text] [Related]
31. Adhesion and migration of extracellular matrix-stimulated breast cancer.
Bartsch JE; Staren ED; Appert HE
J Surg Res; 2003 Mar; 110(1):287-94. PubMed ID: 12697413
[TBL] [Abstract][Full Text] [Related]
32. Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements.
Coleman PJ; Brashear KM; Hunt CA; Hoffman WF; Hutchinson JH; Breslin MJ; McVean CA; Askew BC; Hartman GD; Rodan SB; Rodan GA; Leu CT; Prueksaritanont T; Fernandez-Metzler C; Ma B; Libby LA; Merkle KM; Stump GL; Wallace AA; Lynch JJ; Lynch R; Duggan ME
Bioorg Med Chem Lett; 2002 Jan; 12(1):31-4. PubMed ID: 11738567
[TBL] [Abstract][Full Text] [Related]
33. Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates.
Sanderson PE; Lyle TA; Cutrona KJ; Dyer DL; Dorsey BD; McDonough CM; Naylor-Olsen AM; Chen IW; Chen Z; Cook JJ; Cooper CM; Gardell SJ; Hare TR; Krueger JA; Lewis SD; Lin JH; Lucas BJ; Lyle EA; Lynch JJ; Stranieri MT; Vastag K; Yan Y; Shafer JA; Vacca JP
J Med Chem; 1998 Nov; 41(23):4466-74. PubMed ID: 9804686
[TBL] [Abstract][Full Text] [Related]
34. Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.
De Corte BL; Kinney WA; Liu L; Ghosh S; Brunner L; Hoekstra WJ; Santulli RJ; Tuman RW; Baker J; Burns C; Proost JC; Tounge BA; Damiano BP; Maryanoff BE; Johnson DL; Galemmo RA
Bioorg Med Chem Lett; 2004 Oct; 14(20):5227-32. PubMed ID: 15380233
[TBL] [Abstract][Full Text] [Related]
35. Improved oral absorption of L-365,260, a poorly soluble drug.
Lin JH; Storey DE; Chen IW; Xu X
Biopharm Drug Dispos; 1996 Jan; 17(1):1-15. PubMed ID: 8991487
[TBL] [Abstract][Full Text] [Related]
36. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist.
Swanson DM; Dubin AE; Shah C; Nasser N; Chang L; Dax SL; Jetter M; Breitenbucher JG; Liu C; Mazur C; Lord B; Gonzales L; Hoey K; Rizzolio M; Bogenstaetter M; Codd EE; Lee DH; Zhang SP; Chaplan SR; Carruthers NI
J Med Chem; 2005 Mar; 48(6):1857-72. PubMed ID: 15771431
[TBL] [Abstract][Full Text] [Related]
37. Orally active, nonpeptide oxytocin antagonists.
Evans BE; Leighton JL; Rittle KE; Gilbert KF; Lundell GF; Gould NP; Hobbs DW; DiPardo RM; Veber DF; Pettibone DJ
J Med Chem; 1992 Oct; 35(21):3919-27. PubMed ID: 1331449
[TBL] [Abstract][Full Text] [Related]
38. Nonpeptide alpha(v)beta(3) antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide.
Meissner RS; Perkins JJ; Duong LT; Hartman GD; Hoffman WF; Huff JR; Ihle NC; Leu CT; Nagy RM; Naylor-Olsen A; Rodan GA; Rodan SB; Whitman DB; Wesolowski GA; Duggan ME
Bioorg Med Chem Lett; 2002 Jan; 12(1):25-9. PubMed ID: 11738566
[TBL] [Abstract][Full Text] [Related]
39. Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminus.
Kuo MS; Bock MG; Freidinger RM; Guidotti MT; Lis EV; Pawluczyk JM; Perlow DS; Pettibone DJ; Quigley AG; Reiss DR; Williams PD; Woyden CJ
Bioorg Med Chem Lett; 1998 Nov; 8(21):3081-6. PubMed ID: 9873680
[TBL] [Abstract][Full Text] [Related]
40. Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors.
Muraglia E; Kinzel O; Gardelli C; Crescenzi B; Donghi M; Ferrara M; Nizi E; Orvieto F; Pescatore G; Laufer R; Gonzalez-Paz O; Di Marco A; Fiore F; Monteagudo E; Fonsi M; Felock PJ; Rowley M; Summa V
J Med Chem; 2008 Feb; 51(4):861-74. PubMed ID: 18217703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
